CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Vaccine and control groups for Ad5hr-SIV trial.
Authors
Christopher T. Campbell (462105)
Ian L. Morgan (462108)
+4Â more
Jeffrey C. Gildersleeve (462109)
Marjorie Robert-Guroff (376907)
Sean R. Llewellyn (462106)
Thorsten Damberg (462107)
Publication date
Publisher
Doi
Cite
Abstract
1<p>Prime includes injections at week 0 (oral and intranasal) and week 12 (intratracheal).</p>2<p>Boost refers to injections at week 24 and 36 (both intramuscular).</p
Similar works
Full text
Available Versions
FigShare
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:figshare.com:article/80580...
Last time updated on 12/02/2018